BPC-157, TB-500, Epitalon, MOTS-c, KPV & Semax: A Pharmacist's Guide
A practical comparison of BPC-157, TB-500, Epitalon, MOTS-c, KPV and Semax—and what the available human evidence can and cannot establish.
By Gulf Breeze Apothecary
Published November 4, 2026
The short answer
BPC-157, TB-500, Epitalon, MOTS-c, KPV and Semax are short synthetic peptides that HHS now allows licensed 503A pharmacies to compound for individual patients, under ten conditions set on October 28, 2026. None is FDA-approved. For each, human evidence is limited to small studies, early trials or foreign data, and most findings come from animals. A licensed prescriber and pharmacist can help you weigh that honestly.
New to the policy? Start with Are Peptides Legal Now?.
The six at a glance
The six differ in size, route and how much human data exists. None has a large, controlled human trial behind it.
| Peptide | What it is | Covered routes | Use FDA's advisers reviewed | Human evidence today |
|---|---|---|---|---|
| BPC-157 | 15-amino-acid synthetic peptide based on a fragment of a stomach protein | Subcutaneous, intramuscular, oral, topical | Ulcerative colitis | Three small, uncontrolled pilot reports, about 30 people in total |
| TB-500 | 7-amino-acid fragment of the natural protein thymosin beta-4 | Subcutaneous, intramuscular | Wound healing | No published trials of the fragment; the parent protein has its own human record |
| Epitalon | 4-amino-acid peptide developed by researchers in Russia | Subcutaneous, intramuscular, intermittent courses only | Insomnia | Limited, mostly foreign studies |
| MOTS-c | 16-amino-acid peptide encoded in mitochondrial DNA | Subcutaneous, intramuscular | Obesity, osteoporosis | No trials of MOTS-c itself; one placebo-controlled safety trial of a related analogue |
| KPV | 3-amino-acid fragment of the hormone alpha-MSH | Topical, oral | Wound healing, inflammatory conditions | FDA reviewers found essentially no human exposure data |
| Semax | 7-amino-acid synthetic analogue of a fragment of the hormone ACTH | Intranasal only | Cerebral ischemia, migraine, trigeminal neuralgia | Several hundred intranasal subjects, mostly in Russian studies |
Sources: routes and evidence summaries from the HHS policy, Appendix B (opens in a new tab); reviewed uses from Goodwin (opens in a new tab). A use reviewed by FDA's advisers is not an approved use.
Why the evidence is thin, and what that means for you
The honest summary: these peptides are popular because of animal studies and personal reports, not because of large human trials.
- FDA's own scientists recommended against all six. Their July 2026 review found the available studies short, small and insufficient to establish safety or effectiveness. The advisory committee voted in favor anyway, by margins such as 8–6 and 7–5 (AJMC (opens in a new tab)).
- HHS's case is mostly about quality, not proof of benefit. Its justification for each peptide rests on new lot-level testing, documented real-world use, and the absence of observed harm. That is different from evidence that a peptide works.
- Unpatentable molecules rarely get big trials. Few companies will fund a large trial for a peptide anyone can make, so the evidence gap may persist.
What it means for you: treat any claim of healing, longevity or performance as unproven. A good prescriber will explain the uncertainty, and a good pharmacy will not promise results.
Pharmacy-compounded vs. "research use only"
The molecule may share a name, but the product is not the same. Under the HHS policy, a compounded peptide must come from an FDA-registered, CGMP-compliant manufacturer and pass more than 15 categories of testing, including endotoxin, heavy metals, microbes and sequence identity. A "research use only" vial carries none of those obligations, usually ships with only a purity and mass result, and is not labeled for human use.
Compounded products are also single-ingredient only, carry the label "This is a compounded drug product. Not for resale.", and come with instructions to report side effects to FDA.
For a full checklist, see How to Verify a Legitimate Peptide Pharmacy.
Frequently asked questions
Which peptides did HHS allow pharmacies to compound? Six: BPC-157, TB-500, Epitalon, MOTS-c, KPV and Semax. No other peptide is covered by the October 2026 policy.
Are any of the six FDA-approved? No. Compounded drugs are not FDA-approved, and the policy makes no finding that any of the six is safe or effective.
Can a pharmacy combine two of them in one vial? No. Each compounded product may contain only a single active ingredient, so a listed peptide can't be combined with another peptide or with any other active, such as semaglutide.
Which one has the most human research? Semax has the largest human record, mostly intranasal studies from Russia. BPC-157 has the most public attention, but its published human studies total about 30 people.
Do I need a prescription? Yes. The policy covers only compounding for a named patient with a valid prescription from a licensed prescriber.
Can I get these if I compete in sports? Check with your governing body first. BPC-157 is prohibited by the World Anti-Doping Agency, and the HHS policy does not change sports rules.
Sources
- HHS Enforcement Discretion Policy, conditions and Appendices A–B (opens in a new tab)
- AJMC: FDA panel backs 6 peptides for compounding (opens in a new tab)
- Goodwin: FDA signals potentially evolving stance on peptide compounding (opens in a new tab)
- ABC News: Some wellness peptides will become widely available, HHS says (opens in a new tab)
- USADA: BPC-157 prohibited (opens in a new tab)
General education only, not medical advice. Compounded medications are not FDA-approved and require a prescription. This page does not recommend any peptide, dose or use. Talk with your prescriber about whether any medication is right for you.